PEDIATRICS Vol. 72 No. 5 November 1983, pp. 696-700
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishiguro, Y.
Right arrow Articles by Sugito, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishiguro, Y.
Right arrow Articles by Sugito, T.

Nervous System-Specific Enolase in Serum as a Marker for Neuroblastoma

Yukio Ishiguro MD1, Kanefusa Kato MD1, Takahiro Ito MD1, Masahiro Nagaya MD1, Noboru Yamada MD1, and Tetsuyuki Sugito MD1

1 From the First Department of Surgery, Nagoya University School of Medicine, Showa-ku Nagoya, Department of Biochemistry, Institute for Developmental Research, Aichi Prefectural Colony, Kamiya, Kasugai, Aichi, and Department of Pediatric Surgery, Nagoya First Red Cross Hospital, Nakamura-ku, Nagoya, Japan

Serum levels of nervous system-specific enolase (agrggr form plus ggrggr form) were determined in 18 patients with neuroblastoma and in 40 control infants by means of a sandwich enzyme immunoassay method specific to the ggr subunit (or 14-3-2 protein) of enolase isozymes. Levels in patients with neuroblastoma were elevated (mean, 70.3; range, 6.2 to 330.0 ng/mL) when compared with those of control subjects (4.3 ± 1.7 ng/mL). Most of the patients (6/7), whose serum nervous system-specific enolase level increased more than 100 ng/mL, died within 1 month. Serial measurements in patients with neuroblastoma receiving various therapies have revealed that there was a good correlation between serum nervous system-specific enolase levels and the course of the disease. These results indicate that the nervous system-specific enolase in serum may be a valuable marker for therapeutic monitoring of patients with neuroblastoma, as reported recently in patients with small-cell carcinoma of the lung.

Key Words: nervous system-specific enolase • neuroblastoma • enzyme immunoassay

Submitted on August 26, 1982
Accepted on March 8, 1983




This article has been cited by other articles:


Home page
 Eur Respir JHome page
W. Jordan, J. Hagedohm, J. Wiltfang, G. Laier-Groeneveld, H. Tumani, A. Rodenbeck, E. Ruther, and G. Hajak
Biochemical markers of cerebrovascular injury in sleep apnoea syndrome
Eur. Respir. J., July 1, 2002; 20(1): 158 - 164.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
U. Missler, M. Wiesmann, C. Friedrich, and M. Kaps
S-100 Protein and Neuron-Specific Enolase Concentrations in Blood as Indicators of Infarction Volume and Prognosis in Acute Ischemic Stroke
Stroke, October 1, 1997; 28(10): 1956 - 1960.
[Abstract] [Full Text]